Loading...
Please wait, while we are loading the content...
Similar Documents
The role of circulating tumor cells as a prognostic marker in the adjuvant setting of patients with breast cancer
| Content Provider | Scilit |
|---|---|
| Author | Elmorshidy, Summar Eissa, Hoda H. Sayed, Douaa M. Fattah, Ola N. Abdel Mohamed, Samir S. |
| Copyright Year | 2020 |
| Abstract | Background Still, there is no clinically reliable marker to detect micrometastasis or breast cancer relapse. This study aimed to evaluate the role of circulating tumor cells (CTCs) as a biomarker in patients with nonmetastatic breast cancer. Patients and methods CTC quantification was carried out using flow cytometry for 50 patients with breast cancer postoperatively: before starting, after three cycles, and at the end of adjuvant chemotherapy. The relationship between CTCs and other tumor characteristics and outcomes were studied. Results The median follow-up duration was 35 months. Before starting adjuvant chemotherapy, CTCs were positive (cutoff point ≥5/7.5 ml) in 36% of the patients and decreased to 20% after finishing chemotherapy (P = 0.04). CTCs were detected in 88.9% (n = 16 of 18) of node-positive patients and in 11.1% of node-negative patients (n = 2 of 18, P = 0.04). No significant association was found with tumor size, grading, or hormone receptor status. Distant metastasis was detected in 20% (n = 10 of 50) of patients and was significantly associated with CTCs more than or equal to 5 in 80% of them (n = 8 of 10) (P = 0.01). The presence of more than or equal to 5 CTCs at baseline was associated with a reduction in both the disease-free survival and overall survival (P < 0.001 and P = 0.003, respectively). Baseline CTCs more than or equal to 5/7.5 ml were confirmed as an independent prognostic factor in multivariate Cox hazard regression analysis for disease-free survival (hazard ratio = 3.71; 95% confidence interval = 1.62–8.48; P = 0.002) and overall survival (hazard ratio = 3.14; 95% confidence interval = 1.34–7.37; P = 0.009). Conclusions The current work suggested that the presence of more than or equal to 5 CTCs/7.5 ml at baseline would predict early disease recurrence and reduce the overall survival in patients with nonmetastatic breast cancer receiving adjuvant chemotherapy. |
| Related Links | http://www.jcmrp.eg.net/article.asp?issn=2357-0121;year=2020;volume=5;issue=3;spage=241;epage=247;aulast=Elmorshidy;type=2 |
| File Format | XHTML |
| ISSN | 23570121 |
| DOI | 10.4103/jcmrp.jcmrp_144_18 |
| Journal | Journal of Current Medical Research and Practice |
| Issue Number | 3 |
| Volume Number | 5 |
| Language | English |
| Publisher | Medknow |
| Access Restriction | Open |
| Subject Keyword | Medical Laboratory Technology Circulating Tumor Cells Early Breast Cancer Prognostic Factors in Breast Cancer Journal of Current Medical Research and Practice, Volume 5, Issue 3 |
| Content Type | Text |
| Resource Type | Article |
